Hospital De Santa Maria E.P.E. — Clinical Trial Site

56 Registered trials

16 Currently recruiting

Organisation

Hospital De Santa Maria E.P.E.

Location

Lisbon, Portugal

Identifier

ORG-100028629

Address

Avenida Professor Egas Moniz Piso 3, 1649-028, Portugal

Departments

#2104
3402:Serviço de Oncologia Médica
5803:Oncologia
93149001:Oncologia Médica
Cardiology
Cardiology Department
Centro de Investigação Clínica
Centro Hospitalar Universitario Lisboa Norte- Hospital Santa Maria (#1)
Centro Investigação Clínica
Departamento de Oncologia
Dermatology
Gastroenterology
General Emergency Service
Genetic
Hematolgy
Hematologia e Transplantação de Medula
Hematology
Hematology Department
Medical Oncology
n/a
Neurociências e Saúde Mental
Neurology
Neurology Department
Oftalmologia
Oncologia
Oncologia Médica
Oncology
Paediatrics
Pediatria
Pediatric Service
Pulmonology
reumathology
Rheuatology
Rheumatology
Rheumatology department
Serviço de Dermatologia
Serviço de Hematologia e Transplantação de Medula
Serviço de Oncologia Médica
urology

Clinical trials at this site (56)

Search interface

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/… Not authorised

2022-500410-26-00 Cystic Fibrosis 5
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini… Recruiting

2025-521558-40-00 Pulmonary Hypertension Associated with Interstitial Lun 5 2026-02-12
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Acute myeloid leukemia 5 2025-02-27
3TR-PARTNER-RA Recruiting

2024-511470-79-00 Rheumatoid Arthritis 6 2025-02-11
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat… Recruiting

2023-507536-21-00 Advanced Solid Tumors 7 2024-10-04
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Moderate to Severe Active Systemic Lupus Erythematosus 5 2024-08-28
A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting

2022-500367-12-00 Dermatomyositis 5 2022-11-30
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE… Recruiting

2025-521802-17-00 Erosive/inflammatory osteoarthritis of the hands 5 2026-01-30
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting

2023-503327-26-00 Sjogren's syndrome 5 2024-01-31
Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in… Recruiting

2023-504351-26-01 Pulmonary arterial hypertension (group I) 11 2023-12-06
The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting

2022-502021-18-00 Rheumatoid Arthritis 6 2023-10-12
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended

2023-505394-32-00 chronic graft versus host disease 5 2025-02-06
A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) (… Ended

2024-514283-40-00 Pulmonary Hypertension 4 2024-12-19
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2024-06-17
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03